Response to: Comment on ’Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’ by Zhu

We thank Dr Zhu for his comment1 on our article regarding the non-inferiority of pembrolizumab hybrid dosing in patients with advanced non-small cell lung cancer (NSCLC)2 and the editor for the opportunity to respond to this comment. As we welcome the discussion regarding the implications of our results, we would like to address these critiques, but we also would like to correct misconceptions concerning our results.